Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SToMP-AD senolytic therapy in early Alzheimer's disease
2024-514411-95-00Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI) comparing Dasatinib + quercetin with Placebo (2 arms). Primary endpoint: Safety of dasatinib + quercetin vs placebo. Planned start Dec 2024; status: withdrawn.
02
Drugs
dasatinibquercetin
03
Conditions
Alzheimer's disease (AD)amnestic mild cognitive impairment (MCI)
Beyond the preview
Go deeper on 2024-514411-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514411-95-00.